<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39258623</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1678-8060</ISSN><JournalIssue CitedMedium="Internet"><Volume>119</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Memorias do Instituto Oswaldo Cruz</Title><ISOAbbreviation>Mem Inst Oswaldo Cruz</ISOAbbreviation></Journal><ArticleTitle>Homologous equivalence study of immunogenicity after third dose of Covid-19 vaccine (recombinant) with an interval of six months after the second dose, comparing the interval of eight and 12 weeks between the first two doses.</ArticleTitle><Pagination><StartPage>e240094</StartPage><MedlinePgn>e240094</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e240094</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1590/0074-02760240094</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0074-02762024000101122</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In response to the coronavirus disease 2019 (Covid-19) pandemic, Brazil authorised the Astra Zeneca/Fiocruz vaccine in January 2021. As the Delta variant emerged in May 2021, interval between vaccine doses was adjusted. By September 2021, the Brazilian National Immunisation Program recommended a booster dose for individuals over 70, and later expanded the recommendation to all adults.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Assess the equivalence of IgG antibody response against the Covid-19 S protein before and approximately 28 days after the third dose of a Covid-19 recombinant vaccine. Two groups received initial two doses with intervals of eight and 12 weeks.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a phase IV clinical study, uncontrolled, non-randomised. The study proposes calculating the ratio of geometric means titres (GMT) 28 days after the third dose, with a target ratio of confidence interval (CI) between 0.77 and 1.3.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">In the primary endpoint, there was no equivalence between the eight- and 12-week intervals with a slight variation favouring the eight-week group. Post-third dose, both groups showed increases titres at 28 days, three months, six months and 12 months. Both groups responded similarly to Delta and Omicron BA.1, with a more significant increase for Delta.</AbstractText><AbstractText Label="MAIN CONCLUSIONS" NlmCategory="CONCLUSIONS">The study showed strong and consistent immune response in all age groups receiving the Covid-19 recombinant vaccine. Third dose elicited an increase in GMT by at least three times aligned with Ministry of Health strategies emphasising Bio-Manguinhos crucial role in pandemic control in the country.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vianna</LastName><ForeName>Clarice Monteiro</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0009-0002-6424-3266</Identifier><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz-Fiocruz, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Silva E Sá</LastName><ForeName>Gloria Regina</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Universidade Federal do Estado do Rio de Janeiro, Instituto de Saúde Coletiva, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seid</LastName><ForeName>Maria Vitória Hadland</ForeName><Initials>MVH</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz-Fiocruz, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camacho</LastName><ForeName>Luiz Antonio Bastos</ForeName><Initials>LAB</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz-Fiocruz, Escola Nacional de Saúde Pública, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xavier</LastName><ForeName>Janaína Reis</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz-Fiocruz, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Gama</LastName><ForeName>Vitor Cardoso</ForeName><Initials>VC</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz-Fiocruz, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Castro</LastName><ForeName>Thalita da Matta</ForeName><Initials>TDM</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz-Fiocruz, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dos Santos</LastName><ForeName>Ewerton Alves Portela</ForeName><Initials>EAP</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz-Fiocruz, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Almeida</LastName><ForeName>Camila Dias</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz-Fiocruz, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>Robson Leite de Souza</ForeName><Initials>RLS</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz-Fiocruz, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siqueira</LastName><ForeName>Marilda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de Vírus Respiratórios, Exantemáticos, Enterovírus e Emergências Virais, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maia</LastName><ForeName>Maria de Lourdes de Sousa</ForeName><Initials>MLS</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz-Fiocruz, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferroco</LastName><ForeName>Clara Lucy de Vasconcellos</ForeName><Initials>CLV</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz-Fiocruz, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Araújo</LastName><ForeName>Mia Ferreira</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de Vírus Respiratórios, Exantemáticos, Enterovírus e Emergências Virais, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tort</LastName><ForeName>Luis Fernando López</ForeName><Initials>LFL</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de Vírus Respiratórios, Exantemáticos, Enterovírus e Emergências Virais, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad de la República, Centro Universitario Regional Litoral Norte, Laboratório de Virologia Molecular, Salto, Uruguay.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caetano</LastName><ForeName>Braulia Costa</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de Vírus Respiratórios, Exantemáticos, Enterovírus e Emergências Virais, Rio de Janeiro, RJ, Brasil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017429">Clinical Trial, Phase IV</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Mem Inst Oswaldo Cruz</MedlineTA><NlmUniqueID>7502619</NlmUniqueID><ISSNLinking>0074-0276</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="Y">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="Y">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="Y">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="Y">Immunization, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>11</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>11</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>11</Day><Hour>7</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39258623</ArticleId><ArticleId IdType="pmc">PMC11385827</ArticleId><ArticleId IdType="doi">10.1590/0074-02760240094</ArticleId><ArticleId IdType="pii">S0074-02762024000101122</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2 an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S. Effectiveness of Covid-19 vaccines against the B 1.617.2 (Delta) variant. N Engl J Med. 2021;385(7):585–594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8314739</ArticleId><ArticleId IdType="pubmed">34289274</ArticleId></ArticleIdList></Reference><Reference><Citation>MS  NOTA TÉCNICA No 43/2021-SECOVID/GAB/SECOVID/MS. Dispõe sobre a administração de dose adicional e de dose de reforço de vacinas contra a Covid-19. Brasília. 2021 https://www.gov.br/saude/pt-br/assuntos/covid-19/notas-tecnicas/2021/nota-tecnica-no-43-2021-secovid-gab-secovid-ms.pdf/view</Citation></Reference><Reference><Citation>MS  NOTA TÉCNICA No 59/2021-SECOVID/GAB/SECOVID/MS. Dispõe sobre administração de reforço de vacinas contra a Covid-19 em pessoas com mais de 18 anos. Brasília. 2021 https://www.gov.br/saude/pt-br/assuntos/covid-19/notas-tecnicas/2021/nota-tecnica-no-592021-secovid-gab-secovid-ms.pdf/view</Citation></Reference><Reference><Citation>MS  NOTA TÉCNICA No 65/2021-SECOVID/GAB/SECOVID/MS. Dispõe sobre antecipação do intervalo para dose de reforço de vacinas contra a COVID-19 em pessoas com mais de 18 anos e imunossuprimidos. Brasília. 2021 https://www.gov.br/saude/pt-br/assuntos/covid-19/notas-tecnicas/2021/sei_ms-0024429242-nota-tecnica-65-antecipacao-da-dose-de-reforco.pdf/view</Citation></Reference><Reference><Citation>Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK a substudy of two randomised controlled trials (COV001 and COV002) Lancet. 2021;398(10304):981–990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409975</ArticleId><ArticleId IdType="pubmed">34480858</ArticleId></ArticleIdList></Reference><Reference><Citation>MS  Vacinômetro Covid-19. Brasília. 2021 https://infoms.saude.gov.br/extensions/SEIDIGI_DEMAS_Vacina_C19/SEIDIGI_DEMAS_Vacina_C19.html</Citation></Reference><Reference><Citation>Pauvolid-Corrêa A, Caetano BC, Machado AB, Ferreira MA, Valente N, Neves TK. Sera of patients infected by earlier lineages of SARS-CoV-2 are capable to neutralize later emerged variants of concern. Biol Methods Protoc. 2022;7(1):bpac021–bpac021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9452110</ArticleId><ArticleId IdType="pubmed">36128169</ArticleId></ArticleIdList></Reference><Reference><Citation>Fundação Oswaldo Cruz  A rede genômica Fiocruz. Fiocruz. 2023 https://www.genomahcov.fiocruz.br/gisaid/</Citation></Reference><Reference><Citation>Rahmani A, Montecucco A, Priano L, Mandolini L, Dini G, Durando P. Serological correlates of protection induced by COVID-19 vaccination in the working age population a systematic review and meta-analysis. Vaccines (Basel) 2024;12(5):494–494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11125960</ArticleId><ArticleId IdType="pubmed">38793745</ArticleId></ArticleIdList></Reference><Reference><Citation>Mink S, Reimann P, Fraunberger P. Prognostic value of anti-SARS-CoV-2 antibodies a systematic review. Clin Chem Lab Med. 2024;62(6):1029–1043.</Citation><ArticleIdList><ArticleId IdType="pubmed">38349073</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanna G, Marongiu A, Firinu D, Piras C, Palmas V, Galdiero M. Humoral responses to wild type and ancient BA 1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose. Clin Exp Med. 2024;24(1):12–12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10799790</ArticleId><ArticleId IdType="pubmed">38244064</ArticleId></ArticleIdList></Reference><Reference><Citation>Westrop SJ, Whitaker HJ, Powell AA, Power L, Whillock C, Campbell H. Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England. J Infect. 2022;84(5):692–700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8815191</ArticleId><ArticleId IdType="pubmed">35131335</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang CH, Huang CG, Huang CT, Chen YC, Kung YA, Chen CJ. Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19 A single-blinded, randomized clinical trial. J Clin Virol. 2022;157:10528–10528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9651991</ArticleId><ArticleId IdType="pubmed">36399969</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidel A, Zanoni M. Groß R.Krnavek D.Erdemci-Evin S.von Maltitz P BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA 1 in young adults. Front Immunol. 2022;13:882918–882918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9357986</ArticleId><ArticleId IdType="pubmed">35958601</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>